Drug CostJune 1, 2026·8 min read·By Jacob Posner, Founder & Editor
How Does Medicare Cover Jardiance in 2026?
Jardiance (empagliflozin) is covered under Medicare Part D for type 2 diabetes, heart failure, and chronic kidney disease. Starting January 1, 2026, the Inflation Reduction Act set a Maximum Fair Price of $197 per 30-day supply, a 66 percent reduction from the pre-negotiation list price of $573. Medicare enrollees who also qualify for Part D Extra Help pay roughly $11 per fill. The 2026 Part D annual out-of-pocket cap is $2,100. Prior authorization is standard on most Part D plans. Manufacturer savings cards are blocked by federal law for Medicare patients, but the BI Cares Patient Assistance Program covers patients who cannot afford the $197 price.
Quick Answer: Medicare Part D covers Jardiance (empagliflozin) in 2026 for three FDA-approved indications: type 2 diabetes, heart failure, and chronic kidney disease. The Inflation Reduction Act negotiated a Maximum Fair Price of $197 per 30-day supply, effective January 1, 2026, down from a $573 list price. Prior authorization is required by most Part D plans. The 2026 Part D annual out-of-pocket cap is $2,100. Patients with Part D Extra Help (Low-Income Subsidy) pay roughly $11 per fill. Medicare patients cannot use the manufacturer coupon card due to the federal anti-kickback statute, but the BI Cares patient assistance program is available for those who qualify by income. No generic empagliflozin is available as of 2026.
Jardiance (empagliflozin) is an oral SGLT2 inhibitor developed by Boehringer Ingelheim and Eli Lilly. Medicare covers Jardiance under Part D for three FDA-approved indications as of 2026: glycemic control in adults and children aged 10 and older with type 2 diabetes; reduction of cardiovascular death and hospitalization in adults with heart failure (both reduced and preserved ejection fraction); and slowing the progression of chronic kidney disease. Medicare patients prescribed Jardiance solely for heart failure or chronic kidney disease, even without a type 2 diabetes diagnosis, are equally covered under Part D and equally entitled to the 2026 Maximum Fair Price.
Jardiance was among the first 10 drugs selected for Medicare price negotiation under the Inflation Reduction Act (Public Law 117-169, signed August 16, 2022). The negotiated Maximum Fair Price of $197 per 30-day supply took effect January 1, 2026, representing a 66 percent reduction from the pre-negotiation list price of $573. Because Jardiance is an oral self-administered tablet dispensed at retail pharmacies, it falls entirely under Medicare Part D. There is no HCPCS J-code for Jardiance and it is not billed under Medicare Part B. The drug flows through Part D formularies and the 2026 annual out-of-pocket cap of $2,100 applies. Compare the parallel IRA negotiation for Farxiga (dapagliflozin), another SGLT2 inhibitor with a 2026 Maximum Fair Price of approximately $179 per month, available at Farxiga Medicare coverage.
Before January 2026, Medicare beneficiaries on Jardiance faced annual drug costs of $5,000 or more in the pre-IRA benefit structure. The 2026 Part D redesign also added the Medicare Prescription Payment Plan, which lets patients spread their out-of-pocket costs monthly rather than paying a large lump sum early in the benefit year. Patients with Medicare Part D who also qualify for Extra Help (Low-Income Subsidy) through Social Security pay roughly $11 per Jardiance fill. If you are not yet on Medicare and want to check whether you qualify, the Medicare eligibility page covers all criteria. Patients with incomes near or below the Medicaid threshold should also check Medicaid income limits to see if Medicaid coverage, which carries a $1 to $4 copay, might apply.
What Jardiance Medicare Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same jardiance medicare can cost many times more at a hospital than at your local pharmacy:
2026 Jardiance Medicare Price by Point of Pay
Where you pay
Typical cost
Notes
Medicare Part D (IRA negotiated Maximum Fair Price, 2026)
$197/month maximum
All Part D plans must honor this price by federal law. Actual patient copay depends on coverage phase and plan design; after $2,100 annual OOP is reached, cost drops to $0.
Medicare Part D with Extra Help (Low-Income Subsidy)
Approximately $11/fill
Extra Help (income up to 150% FPL) significantly reduces cost sharing. Apply through Social Security at 1-800-772-1213.
Pharmacy counter (retail cash, no insurance)
$255 - $831/month
Full cash price $550 to $831; with free GoodRx or SingleCare coupon, as low as $255 at Kroger. Not available to Medicare patients.
Medicaid
$1 - $4/prescription
Covered in most states; prior authorization often required. Medicaid income limits vary by state.
BI Cares Patient Assistance Program (no insurance / unaffordable)
$0 (free, income-based)
For uninsured or Medicare patients who cannot afford $197/month. Call 1-800-556-8317. Annual renewal required.
Medicare Part D Maximum Fair Price per CMS IRA negotiation effective January 1, 2026. Retail prices as of Q2 2026 via GoodRx and SingleCare. Medicaid copay range per CMS Medicaid Fee Schedule; state programs vary.
Source: CMS IRA Negotiated Prices 2026, GoodRx, SingleCare, CMS Medicaid
Why Hospitals Charge So Much
Jardiance is an oral self-administered tablet, so inpatient hospital billing is far less common than with injectable drugs. When a Medicare patient is admitted to the hospital and is already taking Jardiance at home, the hospital typically bundles the drug into the DRG (Diagnosis-Related Group) payment under Medicare Part A. In those bundled cases, Jardiance does not appear as a separate patient-facing line item. CMS guidelines recommend stopping SGLT2 inhibitors like Jardiance before surgery or fasting procedures due to the risk of euglycemic diabetic ketoacidosis. Patients should verify they are not billed for Jardiance during a hospital stay where the medication was clinically discontinued.
When Jardiance appears as a separate hospital line item, it typically signals a billing classification issue rather than a legitimate facility charge. The most common scenario is an outpatient observation admission coded such that the drug is billed outside Part D coverage as a hospital outpatient drug charge. Under Medicare Part B outpatient rules, Jardiance is not a Part B drug and has no HCPCS J-code, so any attempt to bill it under Part B or as a standalone facility charge should be challenged. Patients who see Jardiance listed on a hospital bill at $900 to $1,800 for a stay should request an itemized bill, confirm their admission status (inpatient Part A vs. outpatient observation), and if the drug was billed outside Part D, dispute the charge through CMS Hospital Price Transparency procedures.
Lower your hospital bill. Or get it forgiven.
Free in 30 seconds. We check every charge for errors and overcharges, see if you qualify for free care at your hospital, and write a custom dispute letter ready to send. Most patients save hundreds.
Boehringer Ingelheim operates the BI Cares Patient Assistance Program for Medicare patients who cannot afford the $197 Maximum Fair Price and for uninsured patients who do not yet have Medicare. Federal anti-kickback statute (42 U.S.C. Section 1320a-7b) blocks the manufacturer copay savings card for any patient whose prescription is covered by Medicare, Medicaid, TRICARE, or VA. Medicare patients must therefore use the income-based BI Cares PAP rather than the savings card. The contrast with retail pricing is stark: without insurance, Jardiance retails at $550 to $831 per month; qualifying Medicare patients who cannot afford $197 and apply to BI Cares can receive the drug at no cost.
Patient assistance programs for Jardiance Medicare
Manufacturer program
Cost / Benefit
How to apply
BI Cares Patient Assistance Program (Boehringer Ingelheim Cares Foundation)
Free Jardiance (up to 90-day supply) for uninsured or Medicare patients who meet income guidelines; call 1-800-556-8317 for current eligibility
Reduces Jardiance cost to roughly $11/fill for eligible Medicare enrollees; income up to 150% FPL; apply through Social Security at 1-800-772-1213
ssa.gov/medicare/part-d-extra-help
Federal anti-kickback statute (42 U.S.C. Section 1320a-7b) prohibits use of the Jardiance manufacturer savings card by patients covered under Medicare, Medicaid, TRICARE, or VA. Using a manufacturer coupon with a government program is illegal for both the patient and the pharmacist. Medicare Part D enrollees must use the IRA-negotiated $197 Maximum Fair Price. If $197 per month is unaffordable, apply for Part D Extra Help (Low-Income Subsidy) through Social Security at 1-800-772-1213, or contact BI Cares directly at 1-800-556-8317.
Source: NeedyMeds.org, Boehringer Ingelheim Cares Foundation, Social Security Administration Extra Help program
Medicare Part D
Jardiance is a covered Medicare Part D drug under all three of its approved indications in 2026. The formulary tier varies by plan, but most Part D plans place Jardiance on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Prior authorization is a standard Part D plan requirement for Jardiance, meaning your prescriber must document a qualifying diagnosis and, in some cases, show that formulary alternatives were considered. The IRA-negotiated Maximum Fair Price of $197 per 30-day supply applies regardless of formulary tier placement: all Part D plans are federally required to honor the $197 Maximum Fair Price as the patient-facing ceiling, whether Jardiance is on Tier 3 or Tier 5. The 2026 Part D deductible can be up to $615, meaning some enrollees pay deductible-phase costs before reaching the $197 MFP-level coverage. After paying $2,100 in annual out-of-pocket Part D spending, all covered drugs including Jardiance cost $0 for the rest of the calendar year.
Medicare patients who also qualify for the Part D Extra Help program (also called the Low-Income Subsidy, or LIS) pay a dramatically reduced copay for Jardiance. ASPE data from prior benefit years shows that Extra Help-eligible beneficiaries paid approximately $1.67 per month on average for Jardiance. In 2026, with the IRA-negotiated $197 Maximum Fair Price as the ceiling and Extra Help reducing that further, eligible patients pay roughly $11 per fill. Extra Help eligibility requires income at or below 150 percent of the federal poverty level and limited assets. Apply through Social Security at ssa.gov or call 1-800-772-1213. The Medicare Prescription Payment Plan, also available starting 2025, lets any Part D enrollee spread out annual cost-sharing into monthly installments, which can help with Jardiance costs before the $2,100 annual cap is reached.
Common Jardiance Medicare Billing Errors
Jardiance is an oral tablet with no HCPCS J-code. If your Medicare plan is charging more than $197 per 30-day fill in 2026, or if Jardiance appears on a hospital inpatient bill as a separate line item, check for these common billing errors:
Part D plan charged more than $197 per 30-day fill in 2026: the Maximum Fair Price is federally mandated for all Part D plans. Call your plan's member services to request application of the MFP. If the plan declines, file a coverage determination request or contact 1-800-MEDICARE.
Wrong formulary tier applied: Jardiance coded to a Tier 5 specialty tier with a cost-sharing rate that exceeds the $197 MFP. The MFP overrides tier-based cost-sharing for Medicare patients in 2026.
Prior authorization not completed before dispensing: if PA was not submitted or was denied without appeal, you may have been charged the full cash price. Your prescriber's office can retroactively submit PA documentation and request a pharmacy reversal within the plan's claims adjustment window.
Manufacturer savings card applied to a Medicare prescription: if a pharmacist mistakenly ran the Jardiance savings card alongside a Medicare Part D claim, both the patient and pharmacist may have violated the anti-kickback statute. The correct billing pathway for Medicare is through the Part D plan at the $197 MFP.
Inpatient hospital bill includes Jardiance as a separate charge when it should be bundled in the DRG: if you were an inpatient under Medicare Part A, Jardiance should generally be bundled into the DRG payment, not billed separately to you.
Frequently Asked Questions
Does Medicare cover Jardiance in 2026?
Yes. Medicare Part D covers Jardiance (empagliflozin) in 2026 for all three FDA-approved indications: type 2 diabetes, heart failure, and chronic kidney disease. Prior authorization is required by most Part D plans. The Inflation Reduction Act set a Maximum Fair Price of $197 per 30-day supply, effective January 1, 2026, which all Part D plans must honor by federal law. The 2026 Part D annual out-of-pocket cap of $2,100 also applies: once you reach $2,100 in covered drug spending, Jardiance and all other covered drugs cost $0 for the rest of the year.
What is the Jardiance Maximum Fair Price under the IRA for 2026?
The Inflation Reduction Act negotiated a Maximum Fair Price of $197 per 30-day supply of Jardiance, effective January 1, 2026. That is a 66 percent reduction from the pre-negotiation list price of $573. Every Medicare Part D plan, including Medicare Advantage prescription drug plans, is required by federal law to apply this price. If your plan charged more than $197 per fill in 2026, call your plan's member services and request they apply the Maximum Fair Price.
Can I use the Jardiance savings card if I have Medicare?
No. Federal anti-kickback statute (42 U.S.C. Section 1320a-7b) prohibits manufacturer copay cards from being used by any patient covered by Medicare, Medicaid, TRICARE, or VA. The Jardiance manufacturer savings card is for commercially insured patients only. Medicare Part D enrollees benefit from the IRA-negotiated $197 Maximum Fair Price instead. If $197 per month is unaffordable, apply for Part D Extra Help (Low-Income Subsidy) through Social Security at 1-800-772-1213, which can reduce your cost to roughly $11 per fill. The BI Cares Patient Assistance Program is another option for eligible patients.
How do I apply for the BI Cares Patient Assistance Program for Jardiance if I have Medicare?
Call 1-800-556-8317 or visit the BI Cares portal at boehringer-ingelheim.com. Medicare patients must first apply for Part D Extra Help (Low-Income Subsidy) through Social Security before BI Cares can process the application. Gather: proof of household income (tax return or pay stubs), proof of US residency, a valid Jardiance prescription, your prescriber's signed section of the application form, and proof that you applied for Extra Help. Processing takes 10 to 15 business days. If approved, Jardiance is shipped to you or your prescriber's office at no cost.
Is there a generic for Jardiance available in 2026?
No FDA-approved generic empagliflozin is available as of 2026. Jardiance is a small-molecule drug, not a biologic, so biosimilar regulation does not apply. The composition patent is expected to provide exclusivity through approximately 2028 to 2030. When a generic becomes available, prices are expected to fall 80 to 90 percent. Until then, the IRA-negotiated $197 Medicare Maximum Fair Price and the BI Cares patient assistance program are the main cost-reduction options for patients without commercial insurance.
Does Medicare cover Jardiance for heart failure or chronic kidney disease, not just diabetes?
Yes. Medicare Part D covers Jardiance for all three FDA-approved indications in 2026: type 2 diabetes, heart failure (with reduced or preserved ejection fraction), and chronic kidney disease. Patients prescribed Jardiance solely for heart failure or chronic kidney disease, without a diabetes diagnosis, are entitled to full Part D coverage and the IRA-negotiated $197 Maximum Fair Price. Prior authorization documentation requirements may differ by indication, so your prescriber should specify the qualifying diagnosis when submitting the PA.
What if my Medicare Part D plan denies coverage for Jardiance?
File a formal appeal within 60 days of the written denial. Include a prescriber letter documenting medical necessity, particularly citing the heart failure or chronic kidney disease indication if applicable, since step-therapy requirements are harder to justify for non-diabetes indications. Request a peer-to-peer review between your prescriber and the plan's medical director. If denied internally, escalate to the Medicare Part D Independent Review Entity (IRE) by calling 1-800-633-4227. While the appeal is pending, BI Cares (1-800-556-8317) may provide a temporary supply.
How does the Jardiance IRA price compare to Farxiga (dapagliflozin) under Medicare in 2026?
Both Jardiance and Farxiga are SGLT2 inhibitors with IRA-negotiated Medicare Maximum Fair Prices effective January 1, 2026. Jardiance (empagliflozin) is set at $197 per 30-day supply. Farxiga (dapagliflozin) is set at approximately $179 per 30-day supply. Both drugs share the type 2 diabetes, heart failure, and chronic kidney disease indications, though they are not fully interchangeable. If your plan requires step therapy or substitution, discuss with your prescriber before switching, since Jardiance has specific evidence in HFpEF that may differentiate it clinically.
Lower your hospital bill. Or get it forgiven.
Free in 30 seconds. We check every charge for errors and overcharges, see if you qualify for free care at your hospital, and write a custom dispute letter ready to send. Most patients save hundreds.
3. CMS: Medicare Part D Benefit Parameters 2026 — 2026 Part D annual out-of-pocket cap of $2,100 and Part D deductible maximum of $615. Medicare Prescription Payment Plan available starting 2025.
4. FDA Drugs@FDA: Jardiance (empagliflozin) NDA 204629 — FDA Drugs@FDA database entry confirming Jardiance (empagliflozin) approval status, approved indications (type 2 diabetes, heart failure, chronic kidney disease), and labeling history.
5. ASPE HHS: Jardiance Medicare Enrollee Use and Spending — HHS data on Medicare Part D beneficiary use and spending for Jardiance; confirms Extra Help enrollees paid approximately $1.67 per month on average prior to IRA negotiations.
6. NeedyMeds: BI Cares Patient Assistance Program — NeedyMeds directory entry for the Boehringer Ingelheim Cares Foundation Patient Assistance Program; income threshold approximately 400% FPL based on program documentation.
7. Medicare.gov: Help with Drug Costs — Medicare.gov overview of Part D Extra Help (Low-Income Subsidy) program, eligibility up to 150% FPL, and application process through Social Security.